Search the Newsreel

Moderna's Flu Vaccine Could Become Its Fifth Approved Product

Moderna reported Q2 2026 revenue of $145 million, a slight increase from the prior year, alongside a GAAP net loss of $(782) million. The company reiterated its target of up to 10% revenue growth for 2026 and improved its year-end cash projections. A significant …

Modern Innovative Digital Technology Updates Bermuda Office and Confirms Hong Kong Share Registrar

South Dakota Investment Council Trims Holdings in Moderna, Inc. $MRNA

The South Dakota Investment Council reduced its stake in Moderna (NASDAQ: MRNA) by 41.1% in the first quarter, selling 69,478 shares but retaining 99,552 shares valued at approximately $5.1 million. Despite this, institutional ownership remains high at 75.33%, with other major investors increasing positions. …

Moderna, Inc. $MRNA Shares Sold by Bank of Nova Scotia

Bank of Nova Scotia significantly reduced its stake in Moderna (NASDAQ:MRNA) by 87.9% in the first quarter, selling over 56,000 shares. Despite institutional investors owning three-quarters of the company, Moderna missed quarterly earnings estimates, reporting a $3.40 loss per share, though revenue increased by …

Moderna (MRNA) Shares Drop After Q2 Earnings and Forecast Cut

Moderna Q2: Weak Revenue, Strong Pipeline - Here's What Matters Now (NASDAQ:MRNA)

MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback

Moderna beats quarterly revenue estimates ahead of key US flu vaccine decision

Baillie Gifford Reduces Moderna Inc (MRNA) Stake -- Shares Trade at 2.54x GF Value

Baillie Gifford reduced its stake in Moderna Inc (MRNA) by selling 1,779,098 shares at $70.03 each, decreasing its holdings by 8.90%. This transaction reflects Baillie Gifford's long-term investment philosophy focused on sustainable growth, even as Moderna's stock is deemed "Significantly Overvalued" by GuruFocus. Despite …

From biotech to fusion, CFS' new CFO has a plan to tap long-term capital

Commonwealth Fusion Systems (CFS) new CFO, Lorence Kim, formerly of Moderna, emphasizes the critical role of long-term capital access for financing fusion energy development. Kim believes the financial lessons learned from Moderna's capital-intensive biotech journey can be applied to CFS, which faces significant capital …

MRNA Looks 152.3% Overvalued on GF Value™

Moderna Inc (MRNA) is highlighted as 152.3% overvalued according to GuruFocus' GF Value™ metric, trading at $57.49 against an intrinsic value of $22.79 per share. The company is set to release Q2 2026 earnings, with analysts forecasting a loss per share and revenue decline, …

Moderna Q2 preview - cash burn, vaccine sales on focus (MRNA:NASDAQ)

Moderna (MRNA) is set to release its Q2 earnings on Friday, with expectations of a $2 per share loss and a 28% decline in revenue to $103M. The company, known for its COVID-19 vaccine, has been focusing on cost reduction strategies. Investors will be …

Hamilton Wealth LLC Buys 137,118 Shares of Moderna, Inc. $MRNA

Hamilton Wealth LLC significantly increased its stake in Moderna, Inc. (NASDAQ:MRNA) by 130.5% in the first quarter, acquiring an additional 137,118 shares, bringing its total to 242,184 shares valued at over $12.3 million. This comes as other hedge funds also adjusted their positions in …

Moderna Inc (MRNA) suffers a 12.5% weekly break as momentum weakens

The biotechnology stock’s latest weekly close leaves the one-month move under pressure, even as the longer 12-week return remains positive.

Moderna (MRNA) Q2 Earnings: What To Expect

Moderna (MRNA) is set to announce its Q2 earnings this Friday. The market anticipates a 24.8% year-on-year revenue decline, an improvement from the previous year's 41.1% decrease. Despite positive sentiment in the biotechnology sector, Moderna's stock is down, and its current share price exceeds …

Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?

Moderna (MRNA) is preparing to report its second-quarter 2026 earnings, with analysts expecting a decline in sales but an improvement in the bottom line. The company's earnings surprise history is strong, though its current Earnings ESP and Zacks Rank suggest it's not poised for …

China Dairy Stocks Surge on Hopes of a Turn in the Four-Year Raw Milk Price Cycle

Price to sales forward of Modern Innovative Digital Technology Company Limited – HKEX:2322

Moderna, Inc. $MRNA Shares Bought by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. significantly increased its stake in Moderna (NASDAQ: MRNA) by 41.3% in the first quarter of 2026, bringing its total holdings to 69,883 shares valued at $3.55 million. Despite this institutional buying, analysts maintain a cautious outlook with a consensus …

Dimensional Fund Advisors LP Buys 343,216 Shares of Moderna, Inc. $MRNA

Dimensional Fund Advisors LP increased its stake in Moderna, Inc. by 19.2% in the first quarter, acquiring an additional 343,216 shares. The firm now owns over 2.1 million shares valued at approximately $108.2 million. Other institutional investors also adjusted their positions, with hedge funds …

Eversept Partners LP Has $8.11 Million Stock Holdings in Moderna, Inc. $MRNA

Eversept Partners LP reduced its stake in Moderna, Inc. by 40.4% during Q1, now holding 159,708 shares valued at $8.11 million. Despite this, other institutional investors adjusted their positions, and insiders sold a significant number of shares. Analysts currently rate Moderna as "Reduce" with …

Renaissance Technologies LLC Acquires 312,800 Shares of Moderna, Inc. $MRNA

Renaissance Technologies LLC increased its holdings in Moderna, Inc. by 55.0% during the first quarter, adding 312,800 shares to own a total of 881,200 shares valued at $44,765,000. Other institutional investors also made significant moves in Moderna stock. The stock is facing a "Reduce" …

(MRNA) as a Liquidity Pulse for Institutional Tactics

This article provides an in-depth analysis of Moderna Inc. (NASDAQ: MRNA) for institutional traders, focusing on liquidity pulses and tactical strategies. It highlights weak near and mid-term sentiment but a strong long-term outlook, with specific AI-generated trading signals, including entry zones, targets, and stop …

Moderna (MRNA) Laps the Stock Market: Here's Why

Moderna (MRNA) stock closed up 2.89% in the latest trading session, outperforming the S&P 500, Dow, and Nasdaq. The biotechnology company is set to report earnings on July 31, 2026, with an anticipated increase in EPS despite a projected decrease in revenue. Analysts are …

After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy?

Moderna's stock has rallied significantly in 2026, partly due to positive news on its seasonal influenza vaccine. However, the article argues that the rally is not justified due to an underwhelming pipeline with limited game-changing potential outside of a personalized cancer vaccine, ongoing operating …

Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks

This article reviews Q1 earnings for several therapeutics stocks, highlighting Moderna's strong performance with a 260% revenue increase and leading the group in revenue growth. Novavax also exceeded analyst expectations, while United Therapeutics showed the weakest performance. Amgen and Halozyme Therapeutics reported satisfactory quarters, …

Moderna stock stays tied to vaccine demand and cash burn

Moderna's stock remains closely tied to vaccine demand and its significant cash burn, reflecting a business in transition after a sharp decline in revenue from pandemic peaks. The company reported 2025 revenue of $3.0 billion, R&D expenses of $2.7 billion, and a net loss …

Moderna, Inc. Revenue Breakdown – BX:0QF

Moderna, Inc. (0QF) generated 1.54 billion CHF last year, predominantly from its Messenger RNA (mRNA) Medicines segment. This marks a decrease from the previous year's 2.94 billion CHF for the same segment. The United States was the largest contributor to revenue, accounting for 950.53 …

Modern Dental Group Limited Revenue Breakdown – HKEX:3600

Moderna: A Stock to Watch or a Risky Bet?

This article features a Motley Fool Scoreboard episode discussing Moderna (NASDAQ: MRNA) to help investors gain insights into market trends and potential opportunities. While experts analyze Moderna, the article also highlights other investment recommendations from Motley Fool's Stock Advisor, noting Moderna was not among …

Moderna Inc (MRNA) Institutional Confidence

Moderna Inc (MRNA) has an institutional shareholding score of 7.00, placing it 50th out of 155 in the pharmaceuticals industry. The institutional shareholding proportion recently increased by 3.46% quarter-over-quarter, now standing at 78.90%. Fidelity Management & Research Company LLC, BlackRock Institutional Trust Company, N.A., …

Moderna stock may move 4.2% on July 31 earnings release By Investing.com

Moderna Inc. (MRNA) stock is projected to move 4.2% around its July 31 earnings release, according to options data. Historically, the stock has exceeded its implied move in three of the last eight earnings announcements. Notably, its largest post-earnings move in the past two …

Moderna Inc (MRNA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Moderna Inc (MRNA), detailing its current earnings forecast score, analyst ratings, and price targets. It includes expected revenue for the next quarter, past and future EPS, and a peer comparison within the Pharmaceuticals industry. The majority of …

Baillie Gifford (MRNA) discloses 18.2M Moderna shares in latest 13G/A

Baillie Gifford & Co has filed Amendment No. 7 to a Schedule 13G/A, reporting its passive ownership in Moderna, Inc. As of June 30, 2026, the firm beneficially owned 18,206,778 shares of Moderna common stock, which represents 4.59% of the outstanding shares. This filing …

Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know

Moderna (MRNA) is expected to report a year-over-year increase in earnings on lower revenues for the quarter ended June 2026, with an estimated loss of $1.97 per share. Despite a positive year-over-year change in earnings, the Zacks Earnings ESP for Moderna is -2.41%, combined …

Moderna (MRNA) Stock Looks Above Fair Value After Cancer Trial News

Moderna (MRNA) stock has seen an 84.8% return year-to-date, but its current valuation, with a P/S ratio of 10.2x against a tailored P/S of 2.6x, suggests it is overvalued. Despite progress in its cancer program and flu vaccine, the stock's high price reflects investor …